🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

RecruitingPhase 2Ages 18 Years - 80 YearsAllNational Taiwan University Hospital
NCT06528405 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD). Despite knowing this, there is no proven treatment to improve outcomes for people with AKD. Recent studies have shown that drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors can slow down the worsening of chronic kidney disease, help with heart failure, and reduce the risk of death. Now, researchers are looking into whether these drugs can also help prevent acute kidney injury (AKI) and improve outcomes for AKD patients. Our project will explore the use of SGLT2 inhibitors in patients with AKD, with the belief that these drugs can safely reduce the amount of protein (albumin) in the urine and improve kidney health. To address this, investigators plan to conduct a large,

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years and \< 80 years * Diagnosed with acute kidney disease * Estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73m² * Albuminuria \> 100 mg/g or proteinuria \> 300 mg/g (adjusted by urine creatinine) * Diagnosed with diabetes or chronic kidney disease Exclusion Criteria: * Received sodium-glucose cotransporter 2 (SGLT2) inhibitors within 28 days prior to enrollment * Patients with type 1 diabetes * Receiving aggressive immunosuppressive therapy for glomerulonephritis * Obstructive nephropathy * Polycystic kidney disease * Malignancy within 3 months or expected to undergo aggressive treatment such as chemotherapy, radiation therapy, immunotherapy, or targeted therapy in the future * Pregnant or breastfeeding women * Clinically assessed as not having recovered from acute kidney injury * Clinically assessed as at high risk for complications related to SGLT2 inhibitors
💊

What it tests

  • dapagliflozin
  • Other anti-diabetic drug or no anti-diabetic drug
  • empagliflozin
  • canagliflozin
📍

Where

1 site
National Taiwan University Hospital
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy